Welcome to our dedicated page for Mei Pharma SEC filings (Ticker: MEIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MEIP SEC filings page on Stock Titan aggregates U.S. Securities and Exchange Commission documents for MEI Pharma, Inc., including key 8-K current reports that explain its corporate evolution and strategic decisions. These filings provide primary-source detail on both the company’s historical role as a clinical-stage oncology business and its later transition toward a Litecoin-focused digital asset treasury strategy under the Lite Strategy, Inc. name.
Among the most significant filings is an 8-K dated September 10, 2025, in which the company reports an amendment to its certificate of incorporation changing its name to Lite Strategy, Inc. and notes that its common stock will cease trading under the MEIP ticker and begin trading under LITS on the NASDAQ Capital Market. Other 8-Ks describe the private placement used to fund the Litecoin treasury initiative, the subsequent acquisition of Litecoin tokens, and governance developments such as board changes and the appointment of GSR as asset manager for the company’s digital asset treasury.
Additional filings outline material agreements and financial obligations tied to the digital asset strategy, including a master loan agreement with BitGo Prime, LLC that establishes a framework for borrowing digital assets or cash secured by collateral. Earlier filings and related disclosures also reflect the company’s strategic alternatives process, workforce reductions, and changes in its clinical development activities.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the core points of each document, helping users quickly understand amendments to corporate structure, financing terms, treasury arrangements, and other material events. Investors can use this page to locate historical MEIP filings and to trace how the company’s regulatory record supports its rebranding and ticker change to LITS, while also accessing real-time updates as new Lite Strategy, Inc. filings are released.
MEI Pharma director Joshua Riezman was granted a stock option to buy 10,000 shares of common stock at an exercise price of $5.19. The option was granted on 08/08/2025, becomes exercisable in installments and expires on 08/08/2035. The grant vests in 36 equal monthly installments, with the first installment vesting one month after the grant, subject to continued service.
Joshua Riezman, a director of MEI Pharma, Inc. (MEIP), filed an Initial Statement on Form 3 reporting the event date 08/05/2025. The filing states that no securities are beneficially owned by the reporting person. The Form 3 was signed by an attorney-in-fact on 08/20/2025 and includes an Exhibit 24 Power of Attorney.
This Schedule 13G reports that Alexander Schornstein beneficially owns 2,115,000 shares of MEI Pharma common stock, representing 6.53% of the outstanding class based on 32,367,236 shares reported in the issuer's registration statement. The filing states that 1,890,000 shares are held directly and 225,000 shares are held by Camino Capital GmbH, for which Mr. Schornstein is the sole beneficial owner.
The report shows sole voting power over 2,115,000 shares and sole dispositive power over 2,065,000 shares, and includes a certification that the securities were not acquired to change or influence control of the issuer. The filer is identified as a citizen of Germany with a listed residence address.
MEI Pharma, Inc. (MEIP) filed an 8-K dated August 5, 2025 reporting Regulation FD disclosure and other events related to digital asset purchases. The company acquired 929,548 Litecoin (LTC) at an average price of $107.58 during July 30–August 4, 2025, deploying all net proceeds from a PIPE private placement dated July 17, 2025. MEI states it is the first U.S.-listed public company to adopt Litecoin as a primary reserve asset and is implementing a new strategy built on digital asset infrastructure and long-term capital innovation. A press release is furnished as Exhibit 99.1. The filing does not disclose the aggregate USD value of the purchases or additional valuation details.